NCT00587431View on ClinicalTrials.gov

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Prostate Cancer
Interventions
DRUG

GnRh (Leuprolide)

Leuprolide LUPRON

DRUG

Testosterone Gel

Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)

DRUG

Docetaxel

70 mg/m2 given on day o1 of each 3 week cycle

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00587431 - Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter